PCMZL
MCID: PRM129
MIFTS: 35

Primary Cutaneous Marginal Zone B-Cell Lymphoma (PCMZL) malady

Categories: Skin diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Aliases & Descriptions for Primary Cutaneous Marginal Zone B-Cell Lymphoma:

Name: Primary Cutaneous Marginal Zone B-Cell Lymphoma 56 69
Pcmzl 56

Classifications:



External Ids:

Orphanet 56 ORPHA178536
MESH via Orphanet 43 D018442
UMLS via Orphanet 70 C1275321
ICD10 via Orphanet 34 C83.0

Summaries for Primary Cutaneous Marginal Zone B-Cell Lymphoma

MalaCards based summary : Primary Cutaneous Marginal Zone B-Cell Lymphoma, also known as pcmzl, is related to b-cell lymphomas and marginal zone b-cell lymphoma. An important gene associated with Primary Cutaneous Marginal Zone B-Cell Lymphoma is MALT1 (MALT1 Paracaspase), and among its related pathways/superpathways are CLEC7A (Dectin-1) signaling and ICos-ICosL Pathway in T-Helper Cell. The drugs Etoposide and Melphalan have been mentioned in the context of this disorder. Affiliated tissues include b cells, skin and bone.

Related Diseases for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Graphical network of the top 20 diseases related to Primary Cutaneous Marginal Zone B-Cell Lymphoma:



Diseases related to Primary Cutaneous Marginal Zone B-Cell Lymphoma

Symptoms & Phenotypes for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Drugs & Therapeutics for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Drugs for Primary Cutaneous Marginal Zone B-Cell Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 337)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etoposide Approved Phase 2, Phase 3,Phase 1,Early Phase 1 33419-42-0 36462
2
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 4053 460612
3
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
4
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
5
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
6
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1,Early Phase 1 55-98-1 2478
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Ofloxacin Approved Phase 3 82419-36-1 4583
9
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613 2171
10
Thiotepa Approved Phase 2, Phase 3 52-24-4 5453
11
Cefepime Approved Phase 3,Phase 1 88040-23-7 5479537
12
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
13
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
14
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 498142 38904
15
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
16
Morphine Approved, Investigational Phase 3 57-27-2 5288826
17
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
18
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
19
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
20
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
23
Dalteparin Approved Phase 3 9041-08-1
24
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
25
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
26
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
27
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757 53477783
28
Norgestimate Approved Phase 3 35189-28-7 6540478
29
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
30
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
31
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
32 Clavulanic Acid Phase 3
33 Analgesics Phase 3,Phase 1
34 Alkylating Agents Phase 2, Phase 3,Phase 1,Early Phase 1
35 Neurotransmitter Agents Phase 3,Phase 2,Phase 1
36 Amoxicillin-Potassium Clavulanate Combination Phase 3
37 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
38 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 2,Phase 1
39 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
40 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
41 Dermatologic Agents Phase 3,Phase 2,Phase 1
42 Tranquilizing Agents Phase 3,Phase 2
43 Anesthetics Phase 3
44 Anesthetics, Dissociative Phase 3
45 Anesthetics, General Phase 3
46 Anesthetics, Intravenous Phase 3
47 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
48 Anti-Bacterial Agents Phase 3,Phase 1,Phase 2
49 Etoposide phosphate Phase 2, Phase 3,Phase 1,Early Phase 1
50 beta-Lactamase Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 252)
id Name Status NCT ID Phase
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
2 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
3 Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia Unknown status NCT00445497 Phase 3
4 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
7 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
10 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
11 Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases Completed NCT00438958 Phase 3
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
13 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
14 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
15 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
16 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
17 Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma Completed NCT00005590 Phase 3
18 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
19 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3
20 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
21 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
22 Lenalidomide as Maintenance Therapy After Combination Chemotherapy With or Without Rituximab and Stem Cell Transplant in Treating Patients With Persistent or Recurrent Non-Hodgkin Lymphoma That is Resistant to Chemotherapy Unknown status NCT01035463 Phase 1, Phase 2
23 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
24 Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma Unknown status NCT00621036 Phase 2
25 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2
26 Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia Unknown status NCT01016990 Phase 2
27 Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma Completed NCT00394693 Phase 2
28 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2
29 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2
30 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
31 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
32 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
33 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00073918 Phase 2
34 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma Completed NCT00244855 Phase 2
35 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2
36 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2
37 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
38 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2
39 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
40 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2
41 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
42 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
43 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
44 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
45 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
46 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2
47 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2
48 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
49 Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease Completed NCT00448201 Phase 2
50 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2

Search NIH Clinical Center for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Genetic Tests for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Anatomical Context for Primary Cutaneous Marginal Zone B-Cell Lymphoma

MalaCards organs/tissues related to Primary Cutaneous Marginal Zone B-Cell Lymphoma:

39
B Cells, Skin, Bone, Bone Marrow

Publications for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Articles related to Primary Cutaneous Marginal Zone B-Cell Lymphoma:

(show all 38)
id Title Authors Year
1
Paediatric primary cutaneous marginal zone B-cell lymphoma: Does it differ from the adult counterpart? ( 27501236 )
2016
2
Primary Cutaneous Marginal Zone B-Cell Lymphoma Presenting as a Small Mass on Temple Area. ( 27152562 )
2016
3
Primary Cutaneous Marginal Zone B Cell Lymphoma of the Eyelid Skin: Diagnostic Clues and Distinction from Other Ocular Adnexal Disease. ( 26545575 )
2015
4
PD-1, S-100, and CD1a Expression in Pseudolymphomatous Folliculitis, Primary Cutaneous Marginal Zone B-cell Lymphoma (MALT lymphoma), and Cutaneous Lymphoid Hyperplasia. ( 25384543 )
2014
5
Is bone marrow biopsy always indicated in patients with primary cutaneous marginal zone B-cell lymphoma? ( 23954046 )
2013
6
Primary cutaneous marginal zone B-cell lymphoma: response to treatment and disease-free survival in a series of 137 patients. ( 23796549 )
2013
7
Letter: Primary cutaneous marginal zone B cell lymphoma of the face: a challenging diagnosis. ( 22398233 )
2012
8
Bi-clonal, multifocal primary cutaneous marginal zone B-cell lymphoma: report of a case and review of the literature. ( 22809282 )
2012
9
Primary cutaneous marginal zone B-cell lymphoma with anetoderma: spontaneous involution plus de novo clonal expansion. ( 21219395 )
2011
10
Primary cutaneous marginal zone B cell lymphoma in monozygotic twins. ( 22707632 )
2011
11
Recurrent localized primary cutaneous marginal-zone B cell lymphoma. ( 22031653 )
2011
12
Pediatric primary cutaneous marginal zone B-cell lymphoma treated with intralesional rituximab. ( 20542839 )
2010
13
Red nose: primary cutaneous marginal zone B-cell lymphoma. ( 19945162 )
2010
14
Primary cutaneous marginal zone B-cell lymphoma: An atypical case. ( 21199631 )
2010
15
Primary cutaneous marginal zone B-cell lymphoma with amyloid deposition: report of two cases with review of literature. ( 20507739 )
2010
16
CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: A crucial role and a new lymphoma paradigm. ( 19940749 )
2010
17
Primary cutaneous marginal zone B-cell lymphoma: clinical and histological aspects. ( 19771768 )
2009
18
Primary cutaneous marginal zone B-cell lymphomas: are they different from other extranodal marginal zone B-cell lymphomas? ( 19515055 )
2009
19
CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: diagnostic and pathogenetic implications. ( 19718787 )
2009
20
Primary cutaneous marginal zone B-cell lymphomas are targeted by aberrant somatic hypermutation. ( 18704108 )
2009
21
Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. ( 18820662 )
2008
22
Primary cutaneous marginal zone B-cell lymphoma may exhibit both the t(14;18)(q32;q21) IGH/BCL2 and the t(14;18)(q32;q21) IGH/MALT1 translocation: an indicator for clonal transformation towards higher-grade B-cell lymphoma? ( 17519619 )
2007
23
Primary cutaneous marginal zone B-cell lymphoma infiltrating the frontal bone. ( 17324846 )
2007
24
Primary cutaneous marginal zone B-cell lymphoma in a patient with chronic lymphocytic leukaemia. ( 17697078 )
2007
25
Borrelia burgdorferi-associated primary cutaneous marginal-zone B-cell lymphoma: a case report. ( 17823520 )
2007
26
Primary cutaneous marginal zone B-cell lymphoma of MALT type in a child. ( 17163787 )
2006
27
Primary cutaneous marginal zone B-cell lymphoma. ( 16830956 )
2006
28
Topical mechlorethamine and clobetasol in multifocal primary cutaneous marginal zone-B cell lymphoma. ( 16704661 )
2006
29
Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. ( 16753871 )
2006
30
Aberrant nuclear BCL10 expression and lack of t(11;18)(q21;q21) in primary cutaneous marginal zone B-cell lymphoma. ( 16784987 )
2006
31
Primary cutaneous marginal zone B-cell lymphoma (PCMZL-MALT). ( 16870546 )
2006
32
Primary cutaneous marginal zone B-cell lymphoma. ( 16280304 )
2005
33
Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. ( 16172311 )
2005
34
Absence of MALT1 translocations in primary cutaneous marginal zone B-cell lymphoma. ( 15377491 )
2004
35
Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathologic study of 24 asian cases. ( 12883238 )
2003
36
Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. ( 12452864 )
2002
37
Primary cutaneous marginal zone B-cell lymphoma: a report of 9 cases. ( 10426886 )
1999
38
Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. ( 9351568 )
1997

Variations for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Expression for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Search GEO for disease gene expression data for Primary Cutaneous Marginal Zone B-Cell Lymphoma.

Pathways for Primary Cutaneous Marginal Zone B-Cell Lymphoma

GO Terms for Primary Cutaneous Marginal Zone B-Cell Lymphoma

Cellular components related to Primary Cutaneous Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 CBM complex GO:0032449 8.62 BCL10 MALT1

Biological processes related to Primary Cutaneous Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.51 BCL10 MALT1
2 Fc-epsilon receptor signaling pathway GO:0038095 9.49 BCL10 MALT1
3 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.48 BCL10 MALT1
4 T cell receptor signaling pathway GO:0050852 9.46 BCL10 MALT1
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.43 BCL10 MALT1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.4 BCL10 MALT1
7 protein oligomerization GO:0051259 9.37 BCL10 MALT1
8 positive regulation of protein ubiquitination GO:0031398 9.32 BCL10 MALT1
9 positive regulation of T cell activation GO:0050870 9.26 BCL10 MALT1
10 response to molecule of bacterial origin GO:0002237 9.16 BCL10 MALT1
11 response to fungus GO:0009620 8.96 BCL10 MALT1
12 regulation of T cell receptor signaling pathway GO:0050856 8.62 BCL10 MALT1

Molecular functions related to Primary Cutaneous Marginal Zone B-Cell Lymphoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.26 BCL10 IRF4
2 protease binding GO:0002020 9.16 BCL10 MALT1
3 protein self-association GO:0043621 8.96 BCL10 MALT1
4 kinase activator activity GO:0019209 8.62 BCL10 MALT1

Sources for Primary Cutaneous Marginal Zone B-Cell Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....